Cookies That Care!
We respect your privacy and use a limited number of cookies to provide essential functionality and enhance your visit. No third-party advertising cookies involved. For more details, please read our Cookie Policy.
I need a freelancer I am a freelancer Pricing News Intelligence
Want a profile like this one?
Join thousands of news professionals who use Paydesk to showcase their work and get hired by top media outlets.
Get Started
Book Emelie with Paydesk
See how it works

Book Emelie with Paydesk

Make your booking securely through paydesk for these benefits:

1

Preferred Booking Channel

Emelie is more likely to commit to assignments booked through paydesk, as it is a trusted platform that validates the seriousness and legitimacy of each engagement.
2

Insured Bookings for Peace of Mind

We provide basic insurance coverage with each booking on paydesk, giving both you and the media professional confidence and protection while they work for you.
3

Effortless Online Payment

Paydesk offers a payment protection system to ensure payments are only finalized when you are satisfied with the job completion. Freelancers trusts our process that guarantees their efforts are rewarded upon successful delivery of services

Still have questions?

Check FAQ
About Emelie
Emelie Svensson is a journalist based in New York, United States of America.

Experienced print journalist, tv reporter, researcher, fixer, documentary filmmaker. 

Working in New York for eight years, for some of the biggest media outlets in Sweden; Aftonbladet, TV4, Svenska Dagbladet, TT, Swedish Public Radio (SR), Swedish Television (SVT), Göteborgs-Posten. 

Also for foreign media, as a reporter for NRK (Norway), and as a researcher/fixer for BBC (Great Britain) and TF1 (France).
Services
Interview (Video / Broadcast) Vox Pop Documentaries
+8
Topics
Business Politics Current Affairs
+11
Portfolio
New international recommendations for type 2 diabetes – consequences for treatment practice in Norway?
20 Feb 2023  |  tidsskriftet.no  |  English  |  Science & Environment
New international recommendations for anti-hyperglycaemic drugs in type 2 diabetes patients suggest changes to current Norwegian practices and the national clinical guidelines. SGLT2 inhibitors and GLP-1 receptor agonists have been shown to reduce cardiovascular events, kidney disease progression, and mortality. Intensive caloric restriction or bariatric surgery can lead to diabetes remission, proposed as a new primary treatment goal. The European Association for the Study of Diabetes and the American Diabetes Association emphasize a holistic, person-centered approach, combating health inequalities, and promoting universal treatment access. The Norwegian Directorate of Health's guidelines differ, posing challenges for doctors and patients. A debate on medication use and funding is needed, involving stakeholders and authorities. The article suggests that Norwegian doctors should be able to prescribe SGLT2 inhibitors and GLP-1 receptor agonists based on the protective effects and not just HbA1c levels, and inform patients about the potential for diabetes remission through significant weight reduction.
Tags:
Norwegian Directorate of Health European Association for the Study of Diabetes American Diabetes Association European Society of Cardiology Kidney Disease: Improving Global Outcomes SGLT2 inhibitors GLP-1 receptor agonists semaglutide tirzepatide Health & Fitness Medical Science & Environment
Informative
Factuality Scale
Delete Edit
×

Sign up to message Emelie

Already have an account? Log in
Looking for work? Register as a Freelancer
Verify your email to complete registration
We’ve just sent an email to . Please check your inbox and click the link to verify your email address and complete your registration. If you don’t see the email, be sure to check your spam or junk folder.
Didn’t receive the email?

Sign Up to Unlock Profiles

Already have an account? Log in
Looking for work? Register as a Freelancer
Verify your email to complete registration
We’ve just sent an email to . Please check your inbox and click the link to verify your email address and complete your registration. If you don’t see the email, be sure to check your spam or junk folder.
Didn’t receive the email?

Log in